Reporting of prognostic markers: Current problems and development of guidelines for evidence-based practice in the future

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1191-1198

  Riley, R D ^a   Abrams, K R ^a   Sutton, A J ^a   Lambert, P C ^a   Jones, D R ^a   Heney, D ^a   Burchill, S A ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Guidelines; Marker; Meta analysis; Prognosis; Survival analysis; Systematic review

Indexed keywords

DOPAMINE; FERRITIN; HERMES ANTIGEN; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; NEURON SPECIFIC ENOLASE; TUMOR MARKER; VANILMANDELIC ACID;

ANALYTIC METHOD; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DATA ANALYSIS; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GENE EXPRESSION; GROUPS BY AGE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; NEUROBLASTOMA; ONCOGENE MYC; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; STATISTICAL ANALYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VARIANCE;

BRAIN NEOPLASMS; CHILD; CHROMOSOME ABERRATIONS; EVIDENCE-BASED MEDICINE; HUMANS; NEUROBLASTOMA; PRACTICE GUIDELINES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038485778     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600886     Document Type: Review

References (28)

1. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
2. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
3. Altman DG (2001) Systematic reviews of studies of prognostic variables. In Systematic Reviews in Health Care: Meta-analysis in Context, Egger M, Davey Smith G, Altman DG (eds) pp 228-247. London: BMJ Publishing Group
4. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518
5. Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J (1997) The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 33(12): 2092-2097
6. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28(1): 1-9
7. Duchateau L, Pignon JP, Bijnens L, Bertin S, Bourhis J, Sylvester R (2001) Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Controlled Clin Trials 22(5): 538-547
8. Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, Daver A, Buecher B, Conroy T, Dieu L, Bidart JM, Deneux L (2001) Standards, options and recommendations for tumor markers in colorectal cancer. Bull Cancer 88(12): 1177-1206 [French]
9. Egger M, Davey Smith G, Altman DG (eds) (2001) Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group
10. Fleiss JL, Gross AJ (1991) Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 44: 127-139
11. Friedberg B, Watine J, Miedouge M (2001) Unresected colorectal liver metastases: prognostic value of laboratory variables. Gastroenterol Clin Biol 25(11): 962-966
12. Hutchon DJR (2001) Publishing raw data and real time statistical analysis on e-journals. Br Med J 322(7285): 530
13. Lambert PC, Sutton AJ, Abrams KR, Jones DR (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55(1): 86-94
14. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2): 116-128
15. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 18(9): 1888-1899
16. Mott MG, Mann JR, Stiller CA (1997) The United Kingdom Children's Cancer Study Group - the first 20 years of growth and development. Eur J Cancer 33(9): 1448-1452
17. Parker CC, Gospodarowicz M, Warde P (2001) Does age influence the behaviour of localized prostate cancer? BJU Int 87: 629-637
18. Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834
19. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ, Lewis IJ (2003a) A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 39: 19-30
20. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ (2003b) Systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. NHS Health Technology Assessment (No. 97/15/03) 2003. Vol. 7, No. 5
21. Rushton L, Jones DR (1992) Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol 99: 239-246
22. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H (1996) Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer 77(11): 2206-2212.
23. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M (1999) Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 79(11-12): 1752-1760
24. Stewart LA, Clarke MJ (1995) Practical methodology of meta-analyses (overviews) using individual patient data. Cochrane Working Group. Stat Med 14: 2057-2079
25. Stewart LA, Parmar MKB (1993) Meta-analysis of the literature or of individual patient data: is there a difference? The Lancet 341: 418-422
26. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-analysis in Medical Research. London: John Wiley
27. Vale CL, Tierney JF, Stewart LA (2002) Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol 31(1): 107-111
28. Zandbergen EGJ, de Haan RJ, Hijdra A (2001) Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage. Intens Care Med 27: 1661-1667